CA2495527A1 - New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof - Google Patents

New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof Download PDF

Info

Publication number
CA2495527A1
CA2495527A1 CA002495527A CA2495527A CA2495527A1 CA 2495527 A1 CA2495527 A1 CA 2495527A1 CA 002495527 A CA002495527 A CA 002495527A CA 2495527 A CA2495527 A CA 2495527A CA 2495527 A1 CA2495527 A1 CA 2495527A1
Authority
CA
Canada
Prior art keywords
dysfunction
compound
cocoa powder
pharmaceutical formulations
containing rapid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002495527A
Other languages
French (fr)
Other versions
CA2495527C (en
Inventor
Nils-Olof Lindberg
Katarina Lindell
Kristina Thyresson
Alice C. Martino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
McNeil AB
Original Assignee
Pfizer Health Ab
Nils-Olof Lindberg
Katarina Lindell
Kristina Thyresson
Alice C. Martino
Mcneil Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Health Ab, Nils-Olof Lindberg, Katarina Lindell, Kristina Thyresson, Alice C. Martino, Mcneil Ab filed Critical Pfizer Health Ab
Publication of CA2495527A1 publication Critical patent/CA2495527A1/en
Application granted granted Critical
Publication of CA2495527C publication Critical patent/CA2495527C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Confectionery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A sexual-dysfunction-compound-containing rapid-onset pharmaceutical composition that comprises cocoa powder, process for manufacturing the composition and use of the composition in sexual dysfunction therapy.
CA002495527A 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof Expired - Fee Related CA2495527C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0202365-3 2002-08-05
SE0202365A SE0202365D0 (en) 2002-08-05 2002-08-05 New formulation and use thereof
PCT/SE2003/001022 WO2004012702A1 (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Publications (2)

Publication Number Publication Date
CA2495527A1 true CA2495527A1 (en) 2004-02-12
CA2495527C CA2495527C (en) 2008-12-30

Family

ID=20288677

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002495527A Expired - Fee Related CA2495527C (en) 2002-08-05 2003-06-18 New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof

Country Status (15)

Country Link
EP (1) EP1539096A1 (en)
JP (1) JP2005539008A (en)
CN (1) CN1674866B (en)
AR (1) AR040797A1 (en)
AU (1) AU2003239038B2 (en)
BR (1) BR0313224A (en)
CA (1) CA2495527C (en)
IL (1) IL166031A0 (en)
MX (1) MXPA05000978A (en)
NZ (1) NZ537520A (en)
RU (1) RU2312665C2 (en)
SE (1) SE0202365D0 (en)
TW (1) TW200418470A (en)
WO (1) WO2004012702A1 (en)
ZA (1) ZA200500051B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10232113A1 (en) 2002-07-16 2004-01-29 Bayer Ag Medicinal products containing vardenafil hydrochloride trihydrate
DE102005009241A1 (en) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with controlled bioavailability
DE102005009240A1 (en) 2005-03-01 2006-09-07 Bayer Healthcare Ag Dosage forms with improved pharmacokinetic properties
GB0509317D0 (en) * 2005-05-06 2005-06-15 Clarke Anthony Pharmaceutical formulation of apomorphine
DE102010024866A1 (en) * 2010-06-24 2011-12-29 Pharmatech Gmbh Formulation for taste masking
EP3299010B1 (en) 2016-09-21 2022-11-09 LTS Lohmann Therapie-Systeme AG Oral dosage form
EP3758675A1 (en) 2018-03-01 2021-01-06 LTS Lohmann Therapie-Systeme AG Oral dosage form containing theobromine-free cocoa

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755180A (en) * 1986-06-16 1988-07-05 Alza Corporation Dosage form comprising solubility regulating member
FR2717387B1 (en) * 1994-03-17 1996-10-18 Hi Pharmtech Process for the production of chewable tablets based on troxerutin, calcium carbonate, calcium phosphate, arginine aspartate, amoxicillin arginine glutamate.
US6121276A (en) 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
ES2105970B1 (en) * 1995-08-02 1998-07-01 S A L V A T Lab Sa ORAL PHARMACEUTICAL COMPOSITION OF CIPROFLOXACINO, NON-AQUEOUS, STABLE AND WITH IMPROVED ORGANOLEPTIC CHARACTERISTICS.
CA2178021C (en) * 1996-04-19 1999-09-28 Theodore H. Stanley Tobacco substitute
DK0941075T3 (en) * 1997-01-06 2003-07-14 Pfizer Quick-release flavor-masking pharmaceutical dosage form
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
JP2000095710A (en) * 1998-09-21 2000-04-04 Taisho Pharmaceut Co Ltd Oral solid preparation mixed with cacao powder
JP2000119198A (en) * 1998-10-16 2000-04-25 Eisai Co Ltd Phosphodiesterase inhibitor-containing peroral preparation hiding bitterness or the like
US6060094A (en) * 1998-10-30 2000-05-09 Nestec S.A. Method of reducing fat in fat-based coating for confectionery products
SE9803986D0 (en) * 1998-11-23 1998-11-23 Pharmacia & Upjohn Ab New compositions
US6531114B1 (en) * 1999-04-06 2003-03-11 Wm. Wrigley Jr. Company Sildenafil citrate chewing gum formulations and methods of using the same
SI20109A (en) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stable pharmaceutical formulation
US6291471B1 (en) 1998-12-17 2001-09-18 Abb Holdings, Inc. Use of apomorphine for the treatment of organic erectile dysfunction in males
US6455564B1 (en) * 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
CA2378257A1 (en) 1999-08-10 2001-02-15 William E. Sponsel Method for increasing optic nerve, choroidal and retinal blood flow to facilitate the preservation of sight
JP2001114668A (en) * 1999-10-13 2001-04-24 Meiji Seika Kaisha Ltd Chocolate preparation
HUP0400495A3 (en) 1999-12-30 2007-05-02 Tap Pharmaceutical Prod Inc Oral mucosal dosage forms of apomorphine, suitable for the administration via oral mucosal tissue
WO2002005820A1 (en) * 2000-07-19 2002-01-24 Lavipharm Laboratories, Inc. Sildenafil citrate solid dispersions having high water solubility
JP2002193839A (en) * 2000-12-27 2002-07-10 Meiji Seika Kaisha Ltd Cocoa pharmaceutical preparation
AR032556A1 (en) * 2001-02-08 2003-11-12 Pharmacia Corp IMMEDIATE ACTION DRUG FOR THE TREATMENT OF SEXUAL DYSFUNCTION
US20020172732A1 (en) * 2001-03-21 2002-11-21 Wies Ter Laak Composition comprising cocoa

Also Published As

Publication number Publication date
EP1539096A1 (en) 2005-06-15
TW200418470A (en) 2004-10-01
CN1674866B (en) 2012-09-26
RU2312665C2 (en) 2007-12-20
AU2003239038B2 (en) 2008-01-03
AR040797A1 (en) 2005-04-20
BR0313224A (en) 2005-07-05
JP2005539008A (en) 2005-12-22
CA2495527C (en) 2008-12-30
NZ537520A (en) 2006-11-30
CN1674866A (en) 2005-09-28
MXPA05000978A (en) 2005-12-12
ZA200500051B (en) 2006-12-27
IL166031A0 (en) 2006-01-15
RU2005102835A (en) 2005-08-10
WO2004012702A1 (en) 2004-02-12
SE0202365D0 (en) 2002-08-05
AU2003239038A1 (en) 2004-02-23

Similar Documents

Publication Publication Date Title
PT1478339E (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
CA2461517A1 (en) Nicotine formulations comprising cocoa and use thereof
AU2003233010A1 (en) Process for the preparation of 3,3,4,4-tetrafluoropyrrolidine and derivatives thereof
IL165977A (en) Substituted pyrimidinylaminobenzamides , process for the preparation thereof and pharmaceutical compositions comprising the same
IL219397A0 (en) Compounds for the treatment of metabolic disorders, methods of preparing same, and pharmaceutical compositions containing same
CA2458067A1 (en) Use of flibanserin in the treatment of sexual disorders
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
HK1098737A1 (en) Process for the preparation of 1,1,1,3,3-pentafluoro-2-chloropropene and 1,1,1,3,3,3-hexafluoro-2-chloropropane
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
AU2003289888A1 (en) Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders
HUP0400246A3 (en) 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use
HUP0301167A3 (en) Sulfonyl-pyrrolidine derivatives useful for the treatment of neurological disorders, process for their preparation, pharmaceutical compositions containing them and their use
HK1067626A1 (en) Novel 2h-pyridazine-3-one derivatives, pharmaceutical compositions containing the same and a process for the preparation of the active ingredient
AU2002238855A1 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
HUP0400155A3 (en) N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same
IL161428A0 (en) Oligoamine derivatives, methods for the production thereof and pharmaceutical compositions containing the same
WO2003059329A3 (en) Polytartrate composition
CA2451519A1 (en) Tablet comprising cetirizine and pseudoephedrine
CA2495527A1 (en) New sexual-dysfunction-compound-containing rapid-onset pharmaceutical formulations comprising cocoa powder and use thereof
HUP0401577A3 (en) Process for the preparation of 2,4-didezoxyhexoses and 2,4,6-tridezoxyhexoses
CA2461757A1 (en) Nicotine formulations comprising chocolate and use thereof
PT1358159E (en) 3,4-diaminopyridine tartrate and phosphate, pharmaceutical compositions and uses thereof
WO2003075824A3 (en) Process of manufacturing pharmaceutical composition useful for management of tuberculosis
IL158587A0 (en) Novel 5-thio-ss-d-xylopyranoside derivatives, preparation method thereof, pharmaceutical compositions containing same and the therapeutic use thereof
IL162101A (en) Crystalline form of a ribofuranosyluronamide derivative, pharmaceutical compositions comprising it, processes for its preparation and use thereof in the preparation of medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160620